Patents by Inventor Michael Chorny
Michael Chorny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414766Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: April 27, 2023Publication date: December 28, 2023Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11833256Abstract: The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.Type: GrantFiled: June 20, 2018Date of Patent: December 5, 2023Assignees: University of Maryland, Baltimore, The Children's Hospital of PhiladelphiaInventors: Masahiro Iwamoto, Michael Chorny
-
Patent number: 11642414Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: GrantFiled: February 11, 2022Date of Patent: May 9, 2023Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11633485Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.Type: GrantFiled: March 13, 2018Date of Patent: April 25, 2023Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
-
Publication number: 20230048369Abstract: Compositions and methods for mitigating SVD mechanisms in BHV, including non-calcific SVD mechanisms, are provided.Type: ApplicationFiled: January 13, 2021Publication date: February 16, 2023Inventors: Giovanni Ferrari, Antonio Frasca, Yingfei Xue, Andrey Zakharchenko, Michael Chorny, Robert Levy, Ivan Alferiev
-
Publication number: 20220160886Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: February 11, 2022Publication date: May 26, 2022Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11253603Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: GrantFiled: September 17, 2019Date of Patent: February 22, 2022Assignee: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Publication number: 20210000967Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: September 17, 2019Publication date: January 7, 2021Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Publication number: 20200197321Abstract: The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.Type: ApplicationFiled: June 20, 2018Publication date: June 25, 2020Inventors: Masahiro Iwamoto, Michael Chorny
-
Publication number: 20200061199Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.Type: ApplicationFiled: March 13, 2018Publication date: February 27, 2020Inventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
-
Patent number: 9694103Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.Type: GrantFiled: September 7, 2012Date of Patent: July 4, 2017Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Ilia Fishbein, Michael Chorny, Robert J. Levy, Benjamin Yellen, Darryl Williams
-
Publication number: 20170043125Abstract: An apparatus for preloading magnetic particles or cells onto a medical device includes a device carrier and a particle carrier attached over the device carrier. At least one magnet is inserted into the device carrier, the at least one magnet extending inside a section of the device carrier, over which the particle carrier is attached, to attract magnetic particles or cells to the particle carrier when the apparatus is placed in a suspension of magnetic particles or cells. A method for preloading magnetic particles or cells onto a medical device includes attaching one or more magnets to a device carrier, attaching a particle carrier to the device carrier in proximity to the one or more magnets, and inserting the device carrier with the attached particle carrier and the one or more magnets into a suspension containing magnetic particles or cells to preload the particle carrier with magnetic particles or cells.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventors: Robert J. Levy, Mark Battig, Michael Chorny
-
Patent number: 9539339Abstract: A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.Type: GrantFiled: October 25, 2013Date of Patent: January 10, 2017Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Michael Chorny
-
Patent number: 9233163Abstract: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.Type: GrantFiled: December 28, 2011Date of Patent: January 12, 2016Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Robert J. Levy
-
Publication number: 20150290338Abstract: A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.Type: ApplicationFiled: October 25, 2013Publication date: October 15, 2015Inventors: Robert J. Levy, Michael Chorny
-
Patent number: 9095610Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: GrantFiled: September 30, 2013Date of Patent: August 4, 2015Assignees: CHILDREN'S HOSPITAL OF PHILADELPHIA, DREXEL UNIVERSITYInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
-
Patent number: 9084877Abstract: A treatment system includes a magnetic targeting catheter and a plurality of MNP. The MNP may include one or more magnetic field-responsive agents and one or more therapeutic agents. The catheter may include an inner shaft having at least one lumen and a fluid delivery balloon adapted to administer a fluid from the inner shaft into a space surrounding the catheter. An expandable mesh formed of a magnetizable material may surround the fluid delivery balloon. The catheter may further include one or more occlusion balloons for controlling blood flow through a vessel in which the catheter is placed. A method of treating a medical condition may include advancing a magnetic targeting catheter to a site, deploying an expandable mesh connected to the catheter, applying a magnetic field to the mesh and depositing a plurality of MNP or cells loaded with MNP near the mesh.Type: GrantFiled: October 27, 2011Date of Patent: July 21, 2015Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Michael Chorny, Ilia Fishbein
-
Patent number: 9028829Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.Type: GrantFiled: December 15, 2009Date of Patent: May 12, 2015Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Michael Chorny, Vladimir Muzykantov, Elizabeth Hood
-
Publication number: 20150119388Abstract: An ester of ArOH according to the formula R—X—CO—OAr, wherein ArOH is a pharmaceutically active compound selected from the group consisting of SN-38, PI-103, etoposide and fenretinide, wherein a) R is a residue of cholesterol, sitosterol, SN-38, PI-103, etoposide or fenretinide and X is O—CO-L, wherein L is either a direct bond or a linking group including a branched or unbranched hydrocarbyl moiety that may optionally include in-chain or pendant heteroatom substituents and/or cyclic moieties; b) R—X—CO-0 is an all-trans retinoate radical or the 9-cis or 13-cis isomer thereof; or c) R—X— is a branched or unbranched, saturated or unsaturated hydrocarbyl moiety comprising at least 5 carbon atoms and optionally including at least one in-chain or pendant heteroatom substituent and/or cyclic moiety.Type: ApplicationFiled: June 14, 2013Publication date: April 30, 2015Applicant: THE CHILDREN'S HOSPITAL PHILADELPHIAInventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur, Robert J. Levy
-
Publication number: 20140170201Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: ApplicationFiled: September 30, 2013Publication date: June 19, 2014Applicants: Drexel University, The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams